- Home
- BEP vs ROIV Comparison
BEP vs ROIV Comparison
Compare BEP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEP
- ROIV
- Stock Information
- Founded
- BEP 1999
- ROIV 2014
- Country
- BEP Canada
- ROIV United Kingdom
- Employees
- BEP N/A
- ROIV N/A
- Industry
- BEP Electric Utilities: Central
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- BEP Utilities
- ROIV Health Care
- Exchange
- BEP Nasdaq
- ROIV Nasdaq
- Market Cap
- BEP 7.3B
- ROIV 8.6B
- IPO Year
- BEP N/A
- ROIV N/A
- Fundamental
- Price
- BEP $25.63
- ROIV $15.09
- Analyst Decision
- BEP Buy
- ROIV Strong Buy
- Analyst Count
- BEP 8
- ROIV 9
- Target Price
- BEP $31.25
- ROIV $19.94
- AVG Volume (30 Days)
- BEP 364.5K
- ROIV 8.2M
- Earning Date
- BEP 11-07-2025
- ROIV 11-11-2025
- Dividend Yield
- BEP 5.75%
- ROIV N/A
- EPS Growth
- BEP N/A
- ROIV N/A
- EPS
- BEP N/A
- ROIV N/A
- Revenue
- BEP $6,174,000,000.00
- ROIV $23,233,000.00
- Revenue This Year
- BEP $18.12
- ROIV N/A
- Revenue Next Year
- BEP $5.94
- ROIV $248.22
- P/E Ratio
- BEP N/A
- ROIV N/A
- Revenue Growth
- BEP 12.75
- ROIV N/A
- 52 Week Low
- BEP $19.29
- ROIV $8.73
- 52 Week High
- BEP $29.56
- ROIV $16.05
- Technical
- Relative Strength Index (RSI)
- BEP 53.95
- ROIV 78.02
- Support Level
- BEP $25.22
- ROIV $13.81
- Resistance Level
- BEP $25.96
- ROIV $16.05
- Average True Range (ATR)
- BEP 0.44
- ROIV 0.50
- MACD
- BEP 0.09
- ROIV 0.22
- Stochastic Oscillator
- BEP 77.70
- ROIV 77.14
About BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.